Guggenheim downgraded Icosavax to Neutral from Buy without a price target. The analyst cites the pending AstraZeneca (AZN) takeover for the downgrade and believes AstraZeneca is the sole and final interested party in the company.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ICVX:
- Icosavax just downgraded at Jefferies, here’s why
- Icosavax just downgraded at William Blair, here’s why
- M & A News: AstraZeneca’s (NASDAQ:AZN) $1.1B Bet on ICVX Sends Shares Soaring
- Icosavax announces interim results from IVX-A12 trial
- Icosavax to be acquired by AstraZeneca for $15.00 per share in cash, CVR